Equity Profile

TVTX

Travere Therapeutics, Inc.

Health CareBiotechnology$5.8B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Travere Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and successfully commercialize its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TVTX Q2-2026 Earnings Preview

Context

Company Snapshot

Travere Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases. With a market cap of $6 billion, it plays a crucial role in the health care sector, addressing unmet medical needs through its specialized treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+253.42%

Avg Stock Reaction

+0.68%

Last Quarter Recap

In Q1-2026, Travere Therapeutics reported an EPS of $0.05, significantly beating estimates by 116.78%. Following this positive surprise, the stock gained 1.79% the next day.

Management Promises & Guidance

Continued focus on advancing clinical programs.
Commitment to expanding patient access to therapies.
Plans to enhance operational efficiencies.

Expectations

Wall Street Expectations

Overall, expectations for Travere's upcoming earnings are mixed, with the company having a strong track record of beating EPS estimates in recent quarters.

Bull Case

If Travere continues its trend of exceeding EPS estimates, it could signal strong operational performance and investor confidence, potentially leading to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its growth prospects and lead to a decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and will it continue the trend of beating estimates?

Given the company's history of positive surprises, a strong EPS could boost investor sentiment and stock performance.

What guidance will management provide regarding revenue growth and future product development?

Management's outlook on revenue and product pipeline will be crucial for assessing the company's growth trajectory and market confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Travere's ability to leverage recent clinical successes into strong revenue growth this quarter.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating stronger-than-expected performance.

Options pricing suggests a significant move, reflecting market uncertainty that could favor a positive surprise.

Key Risk

If the EPS comes in above $0.10, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Travere can maintain its positive earnings momentum and provide a favorable outlook.

Bull Confirmed If

An EPS of $0.10 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.00 would confirm the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±20.03%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a substantial move of about 20% in either direction, suggesting heightened volatility expectations around the earnings report.

Options are pricing ±20.0% while TVTX has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

43.7%

Calls (138K)P/C Ratio: 0.20Puts (23K)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

115.25%

of float

Insider

0.76%

of float

Holders

380

institutions

Top Holders· as of Dec 2025

Janus Henderson Group PLC
10,511,166 sh · $425.7M
11.38%
-0.8%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Travere beats expectations, history suggests the stock could rise by about 0.68%, confirming strong operational performance.

In-Line / Cautious

If results are in line but cautious, the stock may see muted movement as investors digest the commentary.

Miss

If the company misses expectations, history suggests a potential decline, with an average drop of around 1.10%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of clinical trials for new therapies.
2Management's commentary on patient access initiatives.
3Insights into operational efficiencies and cost management.
4Guidance on revenue expectations for the next quarter.
5Details on competitive positioning in the biotechnology space.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Travere Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and successfully commercialize its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TVTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+253.42%

Avg Stock Reaction

+0.68%

Last Quarter Recap

In Q1-2026, Travere Therapeutics reported an EPS of $0.05, significantly beating estimates by 116.78%. Following this positive surprise, the stock gained 1.79% the next day.

Management Promises & Guidance

Continued focus on advancing clinical programs.
Commitment to expanding patient access to therapies.
Plans to enhance operational efficiencies.

Expectations

Wall Street Expectations

Overall, expectations for Travere's upcoming earnings are mixed, with the company having a strong track record of beating EPS estimates in recent quarters.

Bull Case

If Travere continues its trend of exceeding EPS estimates, it could signal strong operational performance and investor confidence, potentially leading to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its growth prospects and lead to a decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and will it continue the trend of beating estimates?

Given the company's history of positive surprises, a strong EPS could boost investor sentiment and stock performance.

What guidance will management provide regarding revenue growth and future product development?

Management's outlook on revenue and product pipeline will be crucial for assessing the company's growth trajectory and market confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Travere's ability to leverage recent clinical successes into strong revenue growth this quarter.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating stronger-than-expected performance.

Options pricing suggests a significant move, reflecting market uncertainty that could favor a positive surprise.

Key Risk

If the EPS comes in above $0.10, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Travere can maintain its positive earnings momentum and provide a favorable outlook.

Bull Confirmed If

An EPS of $0.10 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.00 would confirm the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±20.03%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a substantial move of about 20% in either direction, suggesting heightened volatility expectations around the earnings report.

Options are pricing ±20.0% while TVTX has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

43.7%

Calls (138K)P/C Ratio: 0.20Puts (23K)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

115.25%

of float

Insider

0.76%

of float

Holders

380

institutions

Top Holders· as of Dec 2025

Janus Henderson Group PLC
10,511,166 sh · $425.7M
11.38%
-0.8%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Travere beats expectations, history suggests the stock could rise by about 0.68%, confirming strong operational performance.

In-Line / Cautious

If results are in line but cautious, the stock may see muted movement as investors digest the commentary.

Miss

If the company misses expectations, history suggests a potential decline, with an average drop of around 1.10%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of clinical trials for new therapies.
2Management's commentary on patient access initiatives.
3Insights into operational efficiencies and cost management.
4Guidance on revenue expectations for the next quarter.
5Details on competitive positioning in the biotechnology space.